On December 18, 2024, Hansoh Pharma, a veteran pharmaceutical company in China, and global pharmaceutical giant Merck jointly announced that they had signed a global exclusive licensing agreement for HS-10535 (an investigational oral small-molecule GLP-1 receptor agonist).This is a major deal with an upfront payment and milestone payments exceeding $2 billion.According to the agreement, Hansoh Pharma grants Merck & Co. the global exclusive license for the development, production, and commercialization of HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments based on the development, regulatory approval, and commercialization progress of the drug candidate. Additionally, Hansoh Pharma will also receive royalties based on product sales.Under specific conditions, Hansoh Pharma may co-promote or exclusively commercialize HS-10535 in China.Currently,Hansoh Pharma has not disclosed more information aboutDetails of HS-10535.
From the publicly disclosed information, Hansoh Pharma has more than one small molecule drug under development in the fields of blood sugar reduction and weight loss, with a rather profound strategic layout.
In January this year, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that HS-10501 tablets, a Class 1 new drug submitted by Hansoh Pharma, had been approved for clinical trials. The drug is intended to be developed for the treatment of adult type 2 diabetes and adult obesity.According to the announcement by Hansoh Pharma, this is also a small-molecule new drug independently developed by the company.As a leading pharmaceutical company in China, Hansoh Pharma has been highly active in out-licensing pipeline transactions in recent years.October 2023,Hansoh Pharma and GSK Reach a Blockbuster Product Licensing Deal Worth Over $1.5 Billion: Hansoh Pharma Grants GSK Global Rights Outside Greater China for Its Self-Developed B7-H4 ADC Project HS-20089, with Hansoh Pharma Receiving an Upfront Payment of $85 Million and Potential Milestone Payments of Up to $1.485 Billion.B7-H3 and B7-H4 are type I transmembrane proteins, belonging to the B7 family. Their abnormalities are associated with many diseases, such as colon cancer, breast cancer, liver cancer, and lung cancer, and have become new targets for immunotherapy.On December 20, 2023, Hansoh Pharma once again entered into a new licensing agreement with GSK, under which GSK will be granted an exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) to develop, manufacture, and commercialize HS-20093, a product developed by Hansoh Pharma.According to the agreement between both parties, the total amount of this transaction exceeds 1.7 billion US dollars, of which Hansoh Pharma will receive an upfront payment of 185 million US dollars and is eligible to receive milestone payments of up to 1.525 billion US dollars upon the achievement of related events for this product.At the same time, after the commercialization of this product, GSK will also pay Hansoh Pharma a tiered royalty on global net sales outside of mainland China, Hong Kong, Macao, and Taiwan.HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) developed by Hansoh Pharma. It is covalently linked by a fully humanized B7-H3 monoclonal antibody and a topoisomerase inhibitor (TOPOi) payload, which can specifically bind to the widely expressed target on solid tumor cells—B7-H3 protein.The upfront payments from the above three outbound licensing deals alone have reached US$382 million (approximately RMB 2.75 billion) for Hansoh Pharma, demonstrating an extremely strong revenue-generating capability.In addition, the milestone payments for the above three transactions total nearly US$5 billion.
Pharmaceutical ResearchReportSharing CampCollect and Share Mainstream Pharmaceutical Research Reports Across the Market
Only 0.8 yuan per day
EnjoyMore than 2000 articlesSelected Medical Research Reports
New additions each yearAdditional 500 Articles
